TR200002625T2 - Vitronektin Reseptörü Antagonistleri - Google Patents

Vitronektin Reseptörü Antagonistleri

Info

Publication number
TR200002625T2
TR200002625T2 TR2000/02625T TR200002625T TR200002625T2 TR 200002625 T2 TR200002625 T2 TR 200002625T2 TR 2000/02625 T TR2000/02625 T TR 2000/02625T TR 200002625 T TR200002625 T TR 200002625T TR 200002625 T2 TR200002625 T2 TR 200002625T2
Authority
TR
Turkey
Prior art keywords
vitronectin receptor
receptor antagonists
restenosis
vitronectin
osteoporosis
Prior art date
Application number
TR2000/02625T
Other languages
English (en)
Inventor
G. Gleason John
Heerding Dirk
M. Samanen James
N. Uzinskas Irene
J. Manley Peter
H. Miller William
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200002625T2 publication Critical patent/TR200002625T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Vitronektin reseptörünü inhibite eden ve enflamasyonu, kanserin ve ateroskleroz ve restenoz gibi kardiyovasküler bozukluklarin ve osteoporoz gibi kemik erimesinin bir etken oldugu hastaliklarin tedavisinde kullanilabilecek, farmasötik olarak aktif bilesimler.
TR2000/02625T 1998-03-10 1999-03-10 Vitronektin Reseptörü Antagonistleri TR200002625T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US9606398P 1998-08-11 1998-08-11

Publications (1)

Publication Number Publication Date
TR200002625T2 true TR200002625T2 (tr) 2000-12-21

Family

ID=26759473

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02625T TR200002625T2 (tr) 1998-03-10 1999-03-10 Vitronektin Reseptörü Antagonistleri

Country Status (24)

Country Link
EP (1) EP1061921A4 (tr)
JP (1) JP2002506033A (tr)
KR (1) KR20010041812A (tr)
CN (1) CN1299282A (tr)
AP (1) AP2000001898A0 (tr)
AR (1) AR015241A1 (tr)
AU (1) AU758498B2 (tr)
BG (1) BG104824A (tr)
BR (1) BR9908636A (tr)
CA (1) CA2323208A1 (tr)
CO (1) CO5080762A1 (tr)
DZ (1) DZ2741A1 (tr)
EA (1) EA200000921A1 (tr)
HU (1) HUP0101143A3 (tr)
ID (1) ID26223A (tr)
IL (1) IL138245A0 (tr)
NO (1) NO20004503L (tr)
OA (1) OA12189A (tr)
PE (1) PE20000323A1 (tr)
PL (1) PL342881A1 (tr)
SK (1) SK13292000A3 (tr)
TR (1) TR200002625T2 (tr)
UY (2) UY25421A1 (tr)
WO (1) WO1999045927A1 (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
US6900232B2 (en) 2000-06-15 2005-05-31 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US20070275956A1 (en) * 2003-10-14 2007-11-29 Lohray Braj B Novel Heterocyclic Compounds
US7678810B2 (en) * 2004-03-05 2010-03-16 Taisho Pharmaceutical Co., Ltd Thiazole derivative
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
BRPI0610506A2 (pt) 2005-04-20 2010-06-29 Johnson & Johnson moduladores de trombina de n-óxidos de piridina fluorados e processo para n-oxidação de heteroarilas contendo nitrogênio
US10059663B2 (en) 2013-08-29 2018-08-28 Kyoto Pharmaceutical Industries, Ltd. Aromatic compound and use thereof
EP4249471A3 (en) 2013-09-24 2023-10-18 FUJIFILM Corporation Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906103A1 (en) * 1995-12-29 1999-04-07 Smithkline Beecham Corporation Vitronectin receptor antagonists
KR19990076876A (ko) * 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제

Also Published As

Publication number Publication date
NO20004503L (no) 2000-10-10
AU2903399A (en) 1999-09-27
ID26223A (id) 2000-12-07
PE20000323A1 (es) 2000-05-24
DZ2741A1 (fr) 2003-09-08
JP2002506033A (ja) 2002-02-26
BR9908636A (pt) 2002-01-08
WO1999045927A1 (en) 1999-09-16
UY25519A1 (es) 1999-12-13
OA12189A (en) 2006-05-09
EP1061921A1 (en) 2000-12-27
HUP0101143A3 (en) 2002-12-28
IL138245A0 (en) 2001-10-31
CN1299282A (zh) 2001-06-13
PL342881A1 (en) 2001-07-16
HUP0101143A2 (hu) 2001-08-28
AR015241A1 (es) 2001-04-18
CO5080762A1 (es) 2001-09-25
SK13292000A3 (sk) 2001-06-11
BG104824A (en) 2001-05-31
CA2323208A1 (en) 1999-09-16
AP2000001898A0 (en) 2000-09-30
AU758498B2 (en) 2003-03-20
UY25421A1 (es) 2001-07-31
EA200000921A1 (ru) 2001-04-23
EP1061921A4 (en) 2005-03-30
NO20004503D0 (no) 2000-09-08
KR20010041812A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
TR200002625T2 (tr) Vitronektin Reseptörü Antagonistleri
NO983003L (no) Vitronectin-reseptor-antagonister
AP1463A (en) Vitronectin receptor antagonists.
DE50010931D1 (de) Substituierte benzimidazole
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
ATE240940T1 (de) Arylsulfonanilid-harnstoffe
MX9603845A (es) Profarmacos de antagonistas del receptor de morfolino-taquiquinina.
AU7001001A (en) Modified forms of pharmacologically active agents and uses therefor
NO20032254L (no) Forbindelser for inhibering av ekspresjon av VACM-I
DE69925133D1 (de) Pyrrolobenzodiazepine
ATE363290T1 (de) Cd40 antagonist zur behandlung von psoriasis
NO20022525D0 (no) Farmasöytiske formuleringer inneholdende zolmitriptan
TR200400228T4 (tr) Psöryazinin tedavisinde kullanılacak maddeler
SI1492773T1 (sl) 4-(heterociklil)-benzensulfoksiminske spojine za zdravljenje vnetja
DE60027077D1 (de) Reinigungszusammensetzung zur Behandlung und/oder Verbesserung von Schuppen, Dermatitis seborrhoeica, Psoriasis und Ekzemen und deren Symptomen
BR9917495A (pt) Derivados o ácido betulìnico tendo atividade antiangiogênica, processos para produzir tais derivados e sua utilização para o tratamento de antiogênese associada a tumores
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
ATE248845T1 (de) Arylsulfonanilid-phosphate
TR200100363T2 (tr) Vitronektin reseptör antagonistleri.
TR200002939T2 (tr) Paroksetin maleat
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
BR9909868A (pt) Ascorbato de paroxetina
MD1136G2 (ro) Unguent antimicotic Verbanov
ECSP972279A (es) Antagonistas del receptor de vitronectina
MY120631A (en) Novel pharmaceutical combination having analgesic activity